378 related articles for article (PubMed ID: 27058452)
1. Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma.
Russell R; Brightling C
Expert Rev Respir Med; 2016 Jun; 10(6):607-17. PubMed ID: 27058452
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
[TBL] [Abstract][Full Text] [Related]
7. Mepolizumab treatment for asthma.
Robinson DS
Expert Opin Biol Ther; 2013 Feb; 13(2):295-302. PubMed ID: 22998420
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
[TBL] [Abstract][Full Text] [Related]
9. Mepolizumab: A Review in Eosinophilic Asthma.
Deeks ED
BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab and exacerbations of refractory eosinophilic asthma.
Haldar P; Brightling CE; Hargadon B; Gupta S; Monteiro W; Sousa A; Marshall RP; Bradding P; Green RH; Wardlaw AJ; Pavord ID
N Engl J Med; 2009 Mar; 360(10):973-84. PubMed ID: 19264686
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.
Iino Y; Takahashi E; Ida S; Kikuchi S
Auris Nasus Larynx; 2019 Apr; 46(2):196-203. PubMed ID: 30122651
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.
Gunsoy NB; Cockle SM; Yancey SW; Keene ON; Bradford ES; Albers FC; Pavord ID
J Allergy Clin Immunol Pract; 2018; 6(3):874-882.e4. PubMed ID: 29258789
[TBL] [Abstract][Full Text] [Related]
13. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report.
Sabbe M; Schleich F; Janssens P; Louis R
J Med Case Rep; 2024 Jan; 18(1):63. PubMed ID: 38291489
[TBL] [Abstract][Full Text] [Related]
14. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
[TBL] [Abstract][Full Text] [Related]
15. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of eosinophilic otitis media associated with severe bronchial asthma with an anti-IL-5 monoclonal antibody, mepolizumab.
Suzaki I; Kimura Y; Tanaka A; Hirano K; Ishibashi A; Mizuyoshi T; Ando I; Kitajima T; Watanabe S; Hinohira Y; Kobayashi H
Auris Nasus Larynx; 2019 Feb; 46(1):141-146. PubMed ID: 29909018
[TBL] [Abstract][Full Text] [Related]
17. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
18. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
19. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma.
Yancey SW; Ortega HG; Keene ON; Mayer B; Gunsoy NB; Brightling CE; Bleecker ER; Haldar P; Pavord ID
J Allergy Clin Immunol; 2017 Apr; 139(4):1167-1175.e2. PubMed ID: 27726946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
